DACT1 (Dishevelled binding antagonist of beta catenin 1) is a multifaceted regulator of Wnt signaling pathways with context-dependent functions in development, disease, and cancer. The protein forms biomolecular condensates through liquid-liquid phase separation via intrinsically disordered domains, which sequester Wnt pathway components like casein kinase 2 to repress canonical Wnt signaling 1. During vertebrate development, DACT1 facilitates convergent extension by inducing Dishevelled oligomerization, promoting binding partner switches and signalosome formation in non-canonical Wnt/planar cell polarity pathways 2. DACT1 expression is upregulated during skeletal muscle differentiation in chicken and mouse models, suggesting roles in myogenesis 3. However, DACT1 exhibits tumor-specific functions in cancer. In colorectal cancer, DACT1 expression correlates with CYCLIN D1 and appears to function as an oncogene 4, while in laryngeal squamous cell carcinoma, DACT1 promotes malignancy and inhibits cuproptosis through PI3K/AKT pathway activation 5. Conversely, DACT1 promoter hypermethylation leads to reduced expression in esophageal squamous cell carcinoma and non-small cell lung cancer, correlating with tumor progression and poor prognosis 67. These findings highlight DACT1's complex, context-dependent roles in normal development versus pathological conditions.